Carenity is a patient-centered digital health company that operates a social platform for people with chronic illnesses and delivers direct-to-patient real‑world evidence (RWE) and market‑research services to life‑science clients. [1][2]
High‑Level Overview
- Mission: Carenity’s stated mission is to empower patients to share experiences, find information, manage illnesses and advance medical knowledge by enabling direct patient engagement and research (“Data for Good”). [1][8]- What it builds / Who it serves: Carenity runs a global digital social platform that supports roughly 500,000 patients and caregivers across 1,200+ conditions and offers research products (custom surveys, PatientLive, RWE studies) for pharma, biotech, medtech, CROs and research organizations. [1][2]- Problem it solves: It connects patients for peer support and creates compliant, timely direct‑to‑patient data collection channels so healthcare organizations can better understand patient experience, improve trial feasibility/recruitment, and inform R&D, market access and post‑launch decisions. [1][2]- Growth momentum: Since founding in 2011 the company has expanded into the US market (platform launched in the US and Boston office opened), introduced new products such as PatientLive (2016), merged into the EvidentIQ group (2021) and has recently undergone leadership transition while positioning as a digital CRO focused on RWE. [1][5]
Origin Story
- Founding and early purpose: Carenity was founded in 2011 to create a patient community and to make patient experience a usable source of insight for research and care improvement. [1]- Founders and leadership evolution: Michael Chekroun is identified as Carenity’s founder and long‑time president; in 2023 he stepped down and Lise Radoszycki (former COO & data science/biostatistics background) became President to lead the next phase of growth within the EvidentIQ group. [5][1]- How the idea emerged / early traction: The platform developed from a patient‑community approach into a research‑oriented offering, publishing RWE studies and launching PatientLive (2016) and the US platform (2018), which signalled a shift from community building to a combined community + research services model. [1][2]
Core Differentiators
- Largest direct patient community focused on chronic illness: Carenity claims a network of ~500k patients and caregivers across 1,200+ diseases, giving scale for condition‑specific sampling and longitudinal observation. [1][2]- Patient‑centric and compliance‑oriented direct‑to‑patient research: Emphasis on compliant, direct access to the patient perspective for RWE, trial feasibility, recruitment/retention and HEOR studies. [1][2]- Product suite geared to life‑science needs: Offerings include custom questionnaires, PatientLive (real‑time insights), barometers/monitoring, conversation analysis (AI/NLP) and classical RWE study execution. [2][1]- Integration with EvidentIQ / CRO capabilities: As part of the EvidentIQ Group, Carenity positions itself as a digital CRO with access to additional scientific and operational resources. [5]- Data science and publication track record: The company highlights a data science team and published RWE studies as part of its credibility for evidence generation. [4][1]
Role in the Broader Tech & Health Landscape
- Trend alignment — RWE and patient centricity: Carenity rides the broader industry shift toward real‑world evidence, patient‑reported outcomes, and direct patient engagement as essential inputs for R&D, regulatory/HTA and market access decisions. [2]- Why timing matters: Regulators and payers increasingly value patient experience and real‑world data, increasing demand for compliant, scalable patient networks and rapid insight tools like PatientLive. [2]- Market forces in their favor: Growth in digital health adoption, the need for decentralized trial solutions, and interest in patient voice for HTA/pricing create addressable demand for Carenity’s platform and services. [2][1]- Influence on ecosystem: By combining a patient community with research delivery, Carenity lowers friction for industry access to patient data and may accelerate decentralized trial recruitment, patient‑led study design and patient‑informed product development. [1][2]
Quick Take & Future Outlook
- Near term: Expect continued expansion of Carenity’s RWE and direct‑to‑patient study offerings, deeper integration with EvidentIQ’s service portfolio, and emphasis on US market growth and productization of real‑time insight tools (PatientLive). [5][1]- Key trends that will shape its path: Regulatory/pricing emphasis on patient‑centered outcomes, broader adoption of decentralized trials, and demand for rapid, compliant patient data will determine growth velocity. [2]- Risks and considerations: Competitive landscape includes other patient panels, RWE providers and CROs; maintaining data quality, privacy/compliance and community trust will be critical to sustain differentiation. [2][1]- Strategic upside: If Carenity continues to scale its patient base, publish robust RWE, and demonstrate operational integration with EvidentIQ, it can strengthen its position as a preferred direct‑to‑patient research partner and amplify the patient voice across drug development and market access. [1][5]
If you want, I can: provide a one‑page investor‑style snapshot (KPIs, revenue/employee estimates, recent milestones), map principal competitors in RWE/patient panels, or summarize a few published RWE studies Carenity has supported.
